OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Oncolytics is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma	171
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	128
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	114
Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering	85
Ferroptosis gene signature in cholangiocarcinoma	68
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy	67
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	62
Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development	55
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo	54
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	53
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	51
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model	50
Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq	50
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	48
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	47
A New Tool for CRISPR-Cas13a-Based Cancer Gene Therapy	45
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy	44
lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC	44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	44
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	43
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer	41
Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA	40
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	40
Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma	39
miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC	39

PROTACs in gastrointestinal cancers	39
AAMP promotes colorectal cancer metastasis by suppressing SMURF2-mediated ubiquitination and degradation of RhoA	36
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	36
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	35
miR-1207-5p suppresses laryngeal squamous cell carcinoma progression by downregulating SKA3 and inhibiting epithelial-mesenchymal transition	35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	35
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	34
Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma	33
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma	33